{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T17:28:00Z","timestamp":1793986080447,"version":"4.8.0"},"reference-count":108,"publisher":"BMJ","issue":"10","content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["Thorax"],"accepted":{"date-parts":[[2019,6,14]]},"published-print":{"date-parts":[[2019,10]]},"abstract":"<jats:p>Respiratory syncytial virus (RSV) is the most common single cause of respiratory hospitalisation of infants and is the second largest cause of lower respiratory infection mortality worldwide. In adults, RSV is an under-recognised cause of deterioration in health, particularly in frail elderly persons. Infection rates typically rise in late autumn and early winter causing bronchiolitis in infants, common colds in adults and insidious respiratory illness in the elderly. Virus detection methods optimised for use in children have low detection rate in adults, highlighting the need for better diagnostic tests. There are many vaccines under development, mostly based on the surface glycoprotein F which exists in two conformations (prefusion and postfusion). Much of the neutralising antibody appears to be to the prefusion form. Vaccines being developed include live attenuated, subunit, particle based and live vectored agents. Different vaccine strategies may be appropriate for different target populations: at-risk infants, school-age children, adult caregivers and the elderly. Antiviral drugs are in clinical trial and may find a place in disease management. RSV disease is one of the major remaining common tractable challenges in infectious diseases and the era of vaccines and antivirals for RSV is on the near horizon.<\/jats:p>","DOI":"10.1136\/thoraxjnl-2018-212212","type":"journal-article","created":{"date-parts":[[2019,8,5]],"date-time":"2019-08-05T17:25:13Z","timestamp":1565025913000},"page":"986-993","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":181,"title":["Respiratory syncytial virus (RSV): a scourge from infancy to old age"],"prefix":"10.1136","volume":"74","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3381-8936","authenticated-orcid":false,"given":"James Andrew","family":"Coultas","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1406-6142","authenticated-orcid":false,"given":"Rosalind","family":"Smyth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter J","family":"Openshaw","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2019,8,5]]},"reference":[{"key":"2024092103300724000_74.10.986.1","first-page":"1191","article-title":"Lower Respiratory Infections Collaborators. Estimates of the global, regional, and national morbidity, mortality, and aetiologies of lower respiratory infections in 195 countries, 1990-2016: a systematic analysis for the Global Burden of Disease Study 2016","volume":"2018","year":"2016","journal-title":"Lancet Infect Dis"},{"key":"2024092103300724000_74.10.986.2","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1814484116"},{"key":"2024092103300724000_74.10.986.3","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1111\/irv.12443","article-title":"Estimating the burden of respiratory syncytial virus (RSV) on respiratory hospital admissions in children less than five years of age in England, 2007-2012","volume":"11","author":"Reeves","year":"2017","journal-title":"Influenza Other Respir Viruses"},{"key":"2024092103300724000_74.10.986.4","doi-asserted-by":"publisher","DOI":"10.1017\/S095026880200729X"},{"key":"2024092103300724000_74.10.986.5","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1093\/oxfordjournals.aje.a121550","article-title":"Epidemiology of respiratory syncytial virus infection in Washington, D.C. I. Importance of the virus in different respiratory tract disease syndromes and temporal distribution of infection","volume":"98","author":"Kim","year":"1973","journal-title":"Am J Epidemiol"},{"key":"2024092103300724000_74.10.986.6","unstructured":"Public Health England . Respiratory syncytial virus (RSV): laboratory reports. Public Health England; 2013. https:\/\/assets.publishing.service.gov.uk\/government\/uploads\/system\/uploads\/attachment_data\/file\/368458\/Laboratory_reports_of_RSV_by_date_of_specimen.pdf"},{"key":"2024092103300724000_74.10.986.7","doi-asserted-by":"publisher","DOI":"10.1097\/INF.0b013e318157da82"},{"key":"2024092103300724000_74.10.986.8","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000000831","article-title":"Respiratory syncytial virus bronchiolitis in children up to 5 years of age in spain: epidemiology and comorbidities: an observational study","volume":"94","author":"Gil-Prieto","year":"2015","journal-title":"Medicine"},{"key":"2024092103300724000_74.10.986.9","unstructured":"Pneumonia Etiology Research for Child Health (PERCH) Study Group . Causes of severe pneumonia requiring hospital admission in children without HIV infection from Africa and Asia: the PERCH multi-country case-control study.. Lancet 2019."},{"key":"2024092103300724000_74.10.986.10","doi-asserted-by":"crossref","first-page":"946","DOI":"10.1016\/S0140-6736(17)30938-8","article-title":"Global, regional, and national disease burden estimates of acute lower respiratory infections due to respiratory syncytial virus in young children in 2015: a systematic review and modelling study","volume":"390","author":"Shi","year":"2017","journal-title":"The Lancet"},{"key":"2024092103300724000_74.10.986.11","doi-asserted-by":"crossref","first-page":"e984","DOI":"10.1016\/S2214-109X(17)30344-3","article-title":"Global respiratory syncytial virus-associated mortality in young children (RSV GOLD): a retrospective case series","volume":"5","author":"Scheltema","year":"2017","journal-title":"Lancet Glob Health"},{"key":"2024092103300724000_74.10.986.12","doi-asserted-by":"crossref","unstructured":"Fleming DM , Taylor RJ , Lustig RL , et al . Modelling estimates of the burden of Respiratory Syncytial virus infection in adults and the elderly in the United Kingdom. BMC Infect Dis 2015;15.doi:10.1186\/s12879-015-1218-z","DOI":"10.1186\/s12879-015-1218-z"},{"key":"2024092103300724000_74.10.986.13","doi-asserted-by":"publisher","DOI":"10.1128\/CMR.13.3.371"},{"key":"2024092103300724000_74.10.986.14","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0031197","article-title":"Comparing pandemic to seasonal influenza mortality: moderate impact overall but high mortality in young children","volume":"7","author":"Wijngaard","year":"2012","journal-title":"PLoS One"},{"key":"2024092103300724000_74.10.986.15","doi-asserted-by":"publisher","DOI":"10.1136\/thx.39.8.624"},{"key":"2024092103300724000_74.10.986.16","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0089186","article-title":"Risk factors for hospital admission with RSV bronchiolitis in England: a population-based birth cohort study","volume":"9","author":"Murray","year":"2014","journal-title":"PLoS One"},{"key":"2024092103300724000_74.10.986.17","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jix400"},{"key":"2024092103300724000_74.10.986.18","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra1413456"},{"key":"2024092103300724000_74.10.986.19","doi-asserted-by":"crossref","unstructured":"Shi T , Balsells E , Wastnedge E , et al . Risk factors for respiratory syncytial virus associated with acute lower respiratory infection in children under five years: Systematic review and meta\u2013analysis. J Glob Health 2015;5.doi:10.7189\/jogh.05.020416","DOI":"10.7189\/jogh.05.020416"},{"key":"2024092103300724000_74.10.986.20","doi-asserted-by":"crossref","unstructured":"Hardelid P , Verfuerden M , McMenamin J , et al . The contribution of child, family and health service factors to respiratory syncytial virushospital admissions in the first three years of life: birth cohort study in Scotland. Eurosurveillance 2018.","DOI":"10.2807\/1560-7917.ES.2019.24.1.1800046"},{"key":"2024092103300724000_74.10.986.21","doi-asserted-by":"publisher","DOI":"10.1086\/380907"},{"key":"2024092103300724000_74.10.986.22","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa043951"},{"key":"2024092103300724000_74.10.986.23","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1007\/s12519-017-0031-8","article-title":"Etiology and clinical features of viral bronchiolitis in infancy","volume":"13","author":"Fretzayas","year":"2017","journal-title":"World J Pediatr"},{"key":"2024092103300724000_74.10.986.24","doi-asserted-by":"publisher","DOI":"10.1542\/peds.2006-2223"},{"key":"2024092103300724000_74.10.986.25","doi-asserted-by":"crossref","first-page":"1259","DOI":"10.1016\/0140-6736(90)91314-Z","article-title":"Clinical findings and severity of acute bronchiolitis","volume":"335","author":"Mulholland","year":"1990","journal-title":"The Lancet"},{"key":"2024092103300724000_74.10.986.26","doi-asserted-by":"crossref","unstructured":"Lambert L , Sagfors AM , Openshaw PJM , et al . Immunity to RSV in Early-Life. Front Immunol 2014;5.doi:10.3389\/fimmu.2014.00466","DOI":"10.3389\/fimmu.2014.00466"},{"key":"2024092103300724000_74.10.986.27","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1067\/S0022-3476(03)00514-6","article-title":"Complications in infants hospitalized for bronchiolitis or respiratory syncytial virus pneumonia","volume":"143","author":"Willson","year":"2003","journal-title":"J Pediatr"},{"key":"2024092103300724000_74.10.986.28","doi-asserted-by":"crossref","first-page":"100201102709029","DOI":"10.1086\/650486","article-title":"The diagnosis of viral respiratory disease in older adults","volume":"50","author":"Talbot","year":"2010","journal-title":"Clin Infect Dis"},{"key":"2024092103300724000_74.10.986.29","doi-asserted-by":"publisher","DOI":"10.2174\/1874285801105010128"},{"key":"2024092103300724000_74.10.986.30","doi-asserted-by":"publisher","DOI":"10.1128\/JCM.42.7.2996-2999.2004"},{"key":"2024092103300724000_74.10.986.31","doi-asserted-by":"publisher","DOI":"10.1111\/j.1469-0691.2005.01223.x"},{"key":"2024092103300724000_74.10.986.32","doi-asserted-by":"publisher","DOI":"10.1016\/S1526-0542(04)90023-1"},{"key":"2024092103300724000_74.10.986.33","doi-asserted-by":"publisher","DOI":"10.1038\/s41579-019-0149-x"},{"key":"2024092103300724000_74.10.986.34","doi-asserted-by":"crossref","unstructured":"Gilman MSA , Castellanos CA , Chen M , et al . Rapid profiling of RSV antibody repertoires from the memory B cells of naturally infected adult donors. Sci Immunol 2016;1. doi: 10.1126\/sciimmunol.aaj1879. [Epub ahead of print: 09 12 2016].doi:10.1126\/sciimmunol.aaj1879","DOI":"10.1126\/sciimmunol.aaj1879"},{"key":"2024092103300724000_74.10.986.35","doi-asserted-by":"crossref","first-page":"3163","DOI":"10.1128\/jvi.61.10.3163-3166.1987","article-title":"Antigenic relatedness between glycoproteins of human respiratory syncytial virus subgroups A and B: evaluation of the contributions of F and G glycoproteins to immunity","volume":"61","author":"Johnson","year":"1987","journal-title":"J Virol"},{"key":"2024092103300724000_74.10.986.36","doi-asserted-by":"crossref","unstructured":"Fuentes S , Klenow L , Golding H , et al . Preclinical evaluation of bacterially produced RSV-G protein vaccine: strong protection against RSV challenge in cotton rat model. Sci Rep 2017;7.doi:10.1038\/srep42428","DOI":"10.1038\/srep42428"},{"key":"2024092103300724000_74.10.986.37","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.94.25.13961"},{"key":"2024092103300724000_74.10.986.38","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.74.14.6442-6447.2000"},{"key":"2024092103300724000_74.10.986.39","doi-asserted-by":"publisher","DOI":"10.1099\/0022-1317-82-3-631"},{"key":"2024092103300724000_74.10.986.40","doi-asserted-by":"publisher","DOI":"10.1006\/bbrc.2000.4093"},{"key":"2024092103300724000_74.10.986.41","doi-asserted-by":"publisher","DOI":"10.1038\/nm.2444"},{"key":"2024092103300724000_74.10.986.42","doi-asserted-by":"publisher","DOI":"10.1007\/978-1-59745-393-6_2"},{"key":"2024092103300724000_74.10.986.43","doi-asserted-by":"publisher","DOI":"10.1006\/viro.2001.1340"},{"key":"2024092103300724000_74.10.986.44","doi-asserted-by":"crossref","first-page":"120502120244005","DOI":"10.1089\/vim.2011.0094","article-title":"Antibodies to the central conserved region of respiratory syncytial virus (RSV) G protein block RSV G protein CX3C-CX3CR1 binding and cross-neutralize RSV A and B strains","volume":"25","author":"Choi","year":"2012","journal-title":"Viral Immunol"},{"key":"2024092103300724000_74.10.986.45","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0130517","article-title":"CX3CR1 is expressed in differentiated human ciliated airway cells and co-localizes with respiratory syncytial virus on cilia in a G protein-dependent manner","volume":"10","author":"Jeong","year":"2015","journal-title":"PLoS One"},{"key":"2024092103300724000_74.10.986.46","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.176.3.1600"},{"key":"2024092103300724000_74.10.986.47","doi-asserted-by":"publisher","DOI":"10.1038\/90675"},{"key":"2024092103300724000_74.10.986.48","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.73.9.7099-7107.1999"},{"key":"2024092103300724000_74.10.986.49","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.01741-13"},{"key":"2024092103300724000_74.10.986.50","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M111.332791"},{"key":"2024092103300724000_74.10.986.51","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.02717-06"},{"key":"2024092103300724000_74.10.986.52","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.173.2.1103"},{"key":"2024092103300724000_74.10.986.53","doi-asserted-by":"publisher","DOI":"10.1099\/jgv.0.000855"},{"key":"2024092103300724000_74.10.986.54","doi-asserted-by":"crossref","first-page":"203","DOI":"10.2217\/imt.15.11","article-title":"Small hydrophobic protein of respiratory syncytial virus as a novel vaccine antigen","volume":"7","author":"Schepens","year":"2015","journal-title":"Immunotherapy"},{"key":"2024092103300724000_74.10.986.55","doi-asserted-by":"publisher","DOI":"10.1099\/vir.0.032987-0"},{"key":"2024092103300724000_74.10.986.56","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.00423-16"},{"key":"2024092103300724000_74.10.986.57","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.201712-2567OC"},{"key":"2024092103300724000_74.10.986.58","doi-asserted-by":"publisher","DOI":"10.1016\/j.virol.2015.05.014"},{"key":"2024092103300724000_74.10.986.59","doi-asserted-by":"publisher","DOI":"10.1155\/2015\/105828"},{"key":"2024092103300724000_74.10.986.60","doi-asserted-by":"publisher","DOI":"10.1086\/428855"},{"key":"2024092103300724000_74.10.986.61","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.78.8.4363-4369.2004"},{"key":"2024092103300724000_74.10.986.62","doi-asserted-by":"crossref","unstructured":"Ascough S , Paterson S , Chiu C . Induction and subversion of human protective immunity: contrasting influenza and respiratory syncytial virus. Front Immunol 2018;9.doi:10.3389\/fimmu.2018.00323","DOI":"10.3389\/fimmu.2018.00323"},{"key":"2024092103300724000_74.10.986.63","doi-asserted-by":"publisher","DOI":"10.1086\/428589"},{"key":"2024092103300724000_74.10.986.64","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.01740-06"},{"key":"2024092103300724000_74.10.986.65","doi-asserted-by":"publisher","DOI":"10.1086\/512615"},{"key":"2024092103300724000_74.10.986.66","doi-asserted-by":"publisher","DOI":"10.1097\/INF.0b013e3181a3ea71"},{"key":"2024092103300724000_74.10.986.67","doi-asserted-by":"publisher","DOI":"10.1086\/520886"},{"key":"2024092103300724000_74.10.986.68","doi-asserted-by":"publisher","DOI":"10.1086\/345859"},{"key":"2024092103300724000_74.10.986.69","doi-asserted-by":"publisher","DOI":"10.1136\/thorax.55.12.1023"},{"key":"2024092103300724000_74.10.986.70","doi-asserted-by":"publisher","DOI":"10.1096\/fj.13-239855"},{"key":"2024092103300724000_74.10.986.71","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/j.ebiom.2016.08.011","article-title":"Determinants of host susceptibility to murine respiratory syncytial virus (RSV) disease identify a role for the innate immunity scavenger receptor MARCO gene in human infants","volume":"11","author":"High","year":"2016","journal-title":"EBioMedicine"},{"key":"2024092103300724000_74.10.986.72","doi-asserted-by":"publisher","DOI":"10.1086\/421524"},{"key":"2024092103300724000_74.10.986.73","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.181.2.976"},{"key":"2024092103300724000_74.10.986.74","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2007-01-069245"},{"key":"2024092103300724000_74.10.986.75","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2567.2006.02405.x"},{"key":"2024092103300724000_74.10.986.76","doi-asserted-by":"publisher","DOI":"10.1136\/thoraxjnl-2012-202288"},{"key":"2024092103300724000_74.10.986.77","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/163.4.693"},{"key":"2024092103300724000_74.10.986.78","doi-asserted-by":"publisher","DOI":"10.1002\/jmv.20724"},{"key":"2024092103300724000_74.10.986.79","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.77.21.11303-11311.2003"},{"key":"2024092103300724000_74.10.986.80","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.201412-2256OC"},{"key":"2024092103300724000_74.10.986.81","doi-asserted-by":"publisher","DOI":"10.1367\/1539-4409(2002)002<0444:PEATCP>2.0.CO;2"},{"key":"2024092103300724000_74.10.986.82","doi-asserted-by":"publisher","DOI":"10.2165\/00003495-199958020-00009"},{"key":"2024092103300724000_74.10.986.83","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199311183292102"},{"key":"2024092103300724000_74.10.986.84","unstructured":"AstraZeneca . US FDA grants Breakthrough Therapy Designation for potential next-generation RSV medicine MEDI8897. US FDA grants Breakthrough Therapy Designation for potential next-generation RSV medicine MEDI8897, 2019. Available: https:\/\/www.astrazeneca.com\/media-centre\/press-releases\/2019\/us-fda-grants-breakthrough-therapy-designation-for-potential-next-generation-rsv-medicine-medi8897.html[Accessed 27 Apr2019]."},{"key":"2024092103300724000_74.10.986.85","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0169139","article-title":"Monoclonal Antibody against G glycoprotein increases respiratory syncytial virus clearance In vivo and prevents vaccine-enhanced diseases","volume":"12","author":"Lee","year":"2017","journal-title":"PLoS One"},{"key":"2024092103300724000_74.10.986.86","doi-asserted-by":"crossref","first-page":"e153","DOI":"10.1016\/S1473-3099(16)00119-5","article-title":"Vaccination against respiratory syncytial virus in pregnancy: a suitable tool to combat global infant morbidity and mortality?","volume":"16","author":"Saso","year":"2016","journal-title":"The Lancet Infectious Diseases"},{"key":"2024092103300724000_74.10.986.87","doi-asserted-by":"publisher","DOI":"10.1093\/oxfordjournals.aje.a120956"},{"key":"2024092103300724000_74.10.986.88","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20020781"},{"key":"2024092103300724000_74.10.986.89","doi-asserted-by":"crossref","unstructured":"Killikelly AM , Kanekiyo M , Graham BS . Pre-fusion F is absent on the surface of formalin-inactivated respiratory syncytial virus. Sci Rep 2016;6.doi:10.1038\/srep34108","DOI":"10.1038\/srep34108"},{"key":"2024092103300724000_74.10.986.90","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(18)30292-5"},{"key":"2024092103300724000_74.10.986.91","unstructured":"Available: https:\/\/path.azureedge.net\/media\/documents\/RSV-snapshot-2018Dec_High_Resolution_V3.pdf.[Accessed 11 Jan2019]."},{"key":"2024092103300724000_74.10.986.92","unstructured":"Novavax Reaches Significant Enrollment Milestone in the Prepare(TM) Phase 3 Trial of its RSV F Vaccine | Novavax Inc. - IR Site. Available: http:\/\/ir.novavax.com\/news-releases\/news-release-details\/novavax-reaches-significant-enrollment-milestone-preparetm-phase [Accessed 11 Jan2019]."},{"key":"2024092103300724000_74.10.986.93","unstructured":"Novavax Announces Topline RSV F Vaccine Data from Two Clinical Trials in Older Adults | Novavax Inc. - IR Site. Available: https:\/\/ir.novavax.com\/news-releases\/news-release-details\/novavax-announces-topline-rsv-f-vaccine-data-two-clinical-trials [Accessed 11 Jan2019]."},{"key":"2024092103300724000_74.10.986.94","unstructured":"Clinical Stage Pipeline \u2013 Novavax. Available: http:\/\/novavax.com\/page\/11\/clinical-stage-pipeline [Accessed 11 Jan2019]."},{"key":"2024092103300724000_74.10.986.95","unstructured":"Novavax . Novavax Announces Topline Results from Phase 3 PrepareTM Trial of ResVaxTM for Prevention of RSV Disease in Infants via Maternal Immunization. Novavax Press Release, 2019. Available: http:\/\/ir.novavax.com\/news-releases\/news-release-details\/novavax-announces-topline-results-phase-3-preparetm-trial [Accessed 16 May2019]."},{"key":"2024092103300724000_74.10.986.96","doi-asserted-by":"crossref","unstructured":"Alansari K , Toaimah FH , Almatar DH , et al . Monoclonal antibody treatment of RSV bronchiolitis in young infants: a randomized trial. Pediatrics 2019;143. doi:10.1542\/peds.2018-2308. [Epub ahead of print: 13 02 2019].","DOI":"10.1542\/peds.2018-2308"},{"key":"2024092103300724000_74.10.986.97","doi-asserted-by":"crossref","unstructured":"Gottlieb J , Torres F , Haddad T , et al . A phase 2b randomized controlled trial of presatovir, an oral RSV fusion inhibitor, for the treatment of respiratory syncytial virus (RSV) in lung transplant (LT) recipients. J Heart Lung Transplant 2018;37.doi:10.1016\/j.healun.2018.01.375","DOI":"10.1016\/j.healun.2018.01.375"},{"key":"2024092103300724000_74.10.986.98","doi-asserted-by":"publisher","DOI":"10.1016\/j.antiviral.2003.07.002"},{"key":"2024092103300724000_74.10.986.99","doi-asserted-by":"publisher","DOI":"10.1183\/09031936.00005610"},{"key":"2024092103300724000_74.10.986.100","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.48.7.2448-2454.2004"},{"key":"2024092103300724000_74.10.986.101","doi-asserted-by":"publisher","DOI":"10.1016\/j.bcp.2016.09.014"},{"key":"2024092103300724000_74.10.986.102","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1413275"},{"key":"2024092103300724000_74.10.986.103","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.79.20.13105-13115.2005"},{"key":"2024092103300724000_74.10.986.104","doi-asserted-by":"crossref","unstructured":"Kazmierski WM . Antiviral drugs: from basic discovery through clinical trials, 2011.","DOI":"10.1002\/9780470929353"},{"key":"2024092103300724000_74.10.986.105","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.40.11.2555"},{"key":"2024092103300724000_74.10.986.106","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M600776200"},{"key":"2024092103300724000_74.10.986.107","doi-asserted-by":"publisher","DOI":"10.1038\/nm896"},{"key":"2024092103300724000_74.10.986.108","unstructured":"PATH . RSV Vaccine and mAb Snapshot, 2018. Available: https:\/\/vaccineresources.org\/files\/RSV-snapshot-2018Dec_High%20Resolution%20V3.pdf [Accessed 28 Feb2019]."}],"container-title":["Thorax"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/thoraxjnl-2018-212212","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,9,21]],"date-time":"2024-09-21T06:30:40Z","timestamp":1726900240000},"score":1,"resource":{"primary":{"URL":"https:\/\/thorax.bmj.com\/lookup\/doi\/10.1136\/thoraxjnl-2018-212212"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,8,5]]},"references-count":108,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2019,9,12]]},"published-print":{"date-parts":[[2019,10]]}},"alternative-id":["10.1136\/thoraxjnl-2018-212212"],"URL":"https:\/\/doi.org\/10.1136\/thoraxjnl-2018-212212","relation":{},"ISSN":["0040-6376","1468-3296"],"issn-type":[{"value":"0040-6376","type":"print"},{"value":"1468-3296","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,8,5]]}}}